AI Article Synopsis

  • This study evaluated four methods for determining permissible analytical imprecision (pCVA%) targets for several immunosuppressive drugs used in clinical settings.
  • The methods considered biological variation, drug elimination half-life, and therapeutic ranges, with results showing average pCVA% values close to each other across the approaches.
  • Although no single optimal method exists, the findings support a target of less than 6% pCVA%, as recommended by professional guidelines.

Article Abstract

Background: Analytical methods require performance that meets the clinical needs. Different approaches for setting up permissible analytical imprecision goals (pCVA%) for drug analyses have been reported. The aim of this study was to calculate the pCVA% for cyclosporine, tacrolimus, everolimus, sirolimus, and mycophenolic acid using 4 alternative approaches, to compare the results and to critically discuss advantages and disadvantages of each model.

Methods: The approaches to evaluate pCVA% were (A) based on biological variation observed in routine measurement results between 2022 and 2023 in the authors' laboratory, (B) derived from the terminal elimination half-life and dosing interval of the drugs, and (C and D) explored from the width of the therapeutic ranges (TR) by the 2 methods. For approach A, routine measurement data for cyclosporine and tacrolimus, obtained through liquid chromatography-tandem mass spectrometry and electrochemiluminescence immunoassays, were evaluated separately.

Results: The 4 alternative approaches for deriving pCVA% yielded similar results, for cyclosporine and tacrolimus in an analytical method dependent manner. The average pCVA% was 5.2%, 5.6%, 5.1%, 4.8%, and 7.7% for cyclosporine, tacrolimus, everolimus, sirolimus, and mycophenolic acid, respectively. The most challenging goals were those using TR-related approaches, while those using the biological variation approach were most easily achievable. Approach B resulted in more stringent goals for drugs with longer elimination half-lives (eg, everolimus and sirolimus).

Conclusions: There is no single ideal approach for setting goals of drug analysis. However, the pCVA% values derived from the various approaches are similar and confirm that a <6% target proposed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology is adequate and realistic in combination with state-of-the-art measurement technologies. In the authors' opinion, approaches based on the width of the TR are preferable, as they represent a common basis for clinical decisions and reflect elements of biological variation and analytics used to establish the TR.

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000001261DOI Listing

Publication Analysis

Top Keywords

cyclosporine tacrolimus
16
tacrolimus everolimus
8
everolimus sirolimus
8
sirolimus mycophenolic
8
mycophenolic acid
8
alternative approaches
8
biological variation
8
routine measurement
8
approaches
6
pcva%
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!